Eli Lilly CEO David Ricks' pay rose to almost $30 million in 2024

Quartz

03-11

David Ricks, Chair and C.E.O. of Eli Lilly and Company, speaks during the New York Times annual DealBook summit at Jazz at Lincoln Center on December 04, 2024 in New York City. - Image: Michael M. Santiago / Staff (Getty Images)

Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.

Ricks’ total compensation for 2024 reached $29.2 million, according to the company’s latest proxy statement, up from $26.6 million in 2023. When he became CEO in 2017, Ricks’ annual compensation started at $15.8 million.

In that time, Eli Lilly has seen explosive growth, largely due to its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.

Both drugs belong to GLP-1 class of treatments, made famous by rival Novo Nordisk’s (NVO) Ozempic. GLP-1s, or incretin medications, mimic gut hormones that regulate blood sugar and curb appetite. Morgan Stanley (MS) analysts anticipate the global market for these drugs will reach $105 billion by 2030.

Mounjaro brought in $11.5 billion in sales in 2024, while Zepbound generated $4.9 billion in annual revenue.

Overall, Eli Lilly’s total sales for the year across all its drugs amounted to $45 billion. The company projects that sales in 2025 will reach between $58 billion and $61 billion.

The company’s strong performance has also boosted its stock price. Eli Lilly’s stock has climbed 10% over the past 12 months to about $842 a share. Over the last five years, the company’s stock has surged nearly 500%

With a market cap of $754 billion, Eli Lilly is now the most valuable healthcare company in the world, ranking 12th overall. For comparison, the next closest healthcare companies are UnitedHealth Group (UNH) and Johnson & Johnson (JNJ), with market caps of $448 billion and $406 billion, respectively.

For the latest news, Facebook, Twitter and Instagram.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2518062192"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518062192\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518062192?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-11 01:16","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2518062192","market":"nz","top_or_hot":-1,"title":"Eli Lilly CEO David Ricks' pay rose to almost $30 million in 2024","media":"Quartz","content":"<html><body><figure>\n<img src=\"https://s.yimg.com/uu/api/res/1.2/UGgNdPX7HZBPPF7epHpCBQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/quartz.com/28cb5583833648ca1f700a24fa487c96\" width=\"600\"/>\n<figcaption>\n  David Ricks, Chair and C.E.O. of Eli Lilly and Company, speaks during the New York Times annual DealBook summit at Jazz at Lincoln Center on December 04, 2024 in New York City. - Image: Michael M. Santiago / Staff (Getty Images)\n </figcaption>\n</figure>\n<p>Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.</p>\n<p>Ricks’ total compensation for 2024 reached $29.2 million, according to the company’s latest proxy statement, up from $26.6 million in 2023. When he became CEO in 2017, Ricks’ annual compensation started at $15.8 million.</p>\n<p>In that time, Eli Lilly has seen explosive growth, largely due to its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.</p>\n<p>Both drugs belong to GLP-1 class of treatments, made famous by rival Novo Nordisk’s (NVO) Ozempic. GLP-1s, or incretin medications, mimic gut hormones that regulate blood sugar and curb appetite. Morgan Stanley (MS) analysts anticipate the global market for these drugs will reach $105 billion by 2030.</p>\n<p>Mounjaro brought in $11.5 billion in sales in 2024, while Zepbound generated $4.9 billion in annual revenue.</p>\n<p>Overall, Eli Lilly’s total sales for the year across all its drugs amounted to $45 billion. The company projects that sales in 2025 will reach between $58 billion and $61 billion.</p>\n<p>The company’s strong performance has also boosted its stock price. Eli Lilly’s stock has climbed 10% over the past 12 months to about $842 a share. Over the last five years, the company’s stock has surged nearly 500%</p>\n<p>With a market cap of $754 billion, Eli Lilly is now the most valuable healthcare company in the world, ranking 12th overall. For comparison, the next closest healthcare companies are UnitedHealth Group (UNH) and Johnson &amp; Johnson (JNJ), with market caps of $448 billion and $406 billion, respectively. </p>\n<p> For the latest news, Facebook, Twitter and Instagram.</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly CEO David Ricks' pay rose to almost $30 million in 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly CEO David Ricks' pay rose to almost $30 million in 2024\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Quartz</strong><span class=\"h-time small\">2025-03-11 01:16</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><figure>\n<img src=\"https://s.yimg.com/uu/api/res/1.2/UGgNdPX7HZBPPF7epHpCBQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/quartz.com/28cb5583833648ca1f700a24fa487c96\" width=\"600\"/>\n<figcaption>\n  David Ricks, Chair and C.E.O. of Eli Lilly and Company, speaks during the New York Times annual DealBook summit at Jazz at Lincoln Center on December 04, 2024 in New York City. - Image: Michael M. Santiago / Staff (Getty Images)\n </figcaption>\n</figure>\n<p>Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.</p>\n<p>Ricks’ total compensation for 2024 reached $29.2 million, according to the company’s latest proxy statement, up from $26.6 million in 2023. When he became CEO in 2017, Ricks’ annual compensation started at $15.8 million.</p>\n<p>In that time, Eli Lilly has seen explosive growth, largely due to its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.</p>\n<p>Both drugs belong to GLP-1 class of treatments, made famous by rival Novo Nordisk’s (NVO) Ozempic. GLP-1s, or incretin medications, mimic gut hormones that regulate blood sugar and curb appetite. Morgan Stanley (MS) analysts anticipate the global market for these drugs will reach $105 billion by 2030.</p>\n<p>Mounjaro brought in $11.5 billion in sales in 2024, while Zepbound generated $4.9 billion in annual revenue.</p>\n<p>Overall, Eli Lilly’s total sales for the year across all its drugs amounted to $45 billion. The company projects that sales in 2025 will reach between $58 billion and $61 billion.</p>\n<p>The company’s strong performance has also boosted its stock price. Eli Lilly’s stock has climbed 10% over the past 12 months to about $842 a share. Over the last five years, the company’s stock has surged nearly 500%</p>\n<p>With a market cap of $754 billion, Eli Lilly is now the most valuable healthcare company in the world, ranking 12th overall. For comparison, the next closest healthcare companies are UnitedHealth Group (UNH) and Johnson &amp; Johnson (JNJ), with market caps of $448 billion and $406 billion, respectively. </p>\n<p> For the latest news, Facebook, Twitter and Instagram.</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/eli-lilly-ceo-david-ricks-171623903.html\">Quartz</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z9P08.USD","symbol_name":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/eli-lilly-ceo-david-ricks-171623903.html","article_id":"2518062192","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518062192","pubTimestamp":1741626983,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"David Ricks, Chair and C.E.O. of Eli Lilly and Company, speaks during the New York Times annual DealBook summit at Jazz at Lincoln Center on December 04, 2024 in New York City. - Image: Michael M. Santiago / Staff . Eli Lilly  CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.Ricks’ total compensation for 2024 reached $29.2 million, according to the company’s latest proxy statement, up from $26.6 million in 2023. When he became CEO in 2017, Ricks’ annual compensation started at $15.8 million.In that time, Eli Lilly has seen explosive growth, largely due to its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.Mounjaro brought in $11.5 billion in sales in 2024, while Zepbound generated $4.9 billion in annual revenue.The company’s strong performance has also boosted its stock price. Eli Lilly’s stock has climbed 10% over the past 12 months to about $8","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","BK4568":"美国抗疫概念","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU2063271972.USD":"富兰克林创新领域基金","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH  \"AG\" (USD) ACC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","SG9999001176.USD":"United Global Healthcare Acc USD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","JNJ":"强生","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4007":"制药","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LLY":"礼来","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A"},"translate_title":"礼来公司首席执行官David Ricks的薪酬到2024年将增至近3000万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.6,"LLY":0.6},"content_text":"David Ricks, Chair and C.E.O. of Eli Lilly and Company, speaks during the New York Times annual DealBook summit at Jazz at Lincoln Center on December 04, 2024 in New York City. - Image: Michael M. Santiago / Staff (Getty Images)\n \n\nEli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.\nRicks’ total compensation for 2024 reached $29.2 million, according to the company’s latest proxy statement, up from $26.6 million in 2023. When he became CEO in 2017, Ricks’ annual compensation started at $15.8 million.\nIn that time, Eli Lilly has seen explosive growth, largely due to its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.\nBoth drugs belong to GLP-1 class of treatments, made famous by rival Novo Nordisk’s (NVO) Ozempic. GLP-1s, or incretin medications, mimic gut hormones that regulate blood sugar and curb appetite. Morgan Stanley (MS) analysts anticipate the global market for these drugs will reach $105 billion by 2030.\nMounjaro brought in $11.5 billion in sales in 2024, while Zepbound generated $4.9 billion in annual revenue.\nOverall, Eli Lilly’s total sales for the year across all its drugs amounted to $45 billion. The company projects that sales in 2025 will reach between $58 billion and $61 billion.\nThe company’s strong performance has also boosted its stock price. Eli Lilly’s stock has climbed 10% over the past 12 months to about $842 a share. Over the last five years, the company’s stock has surged nearly 500%\nWith a market cap of $754 billion, Eli Lilly is now the most valuable healthcare company in the world, ranking 12th overall. For comparison, the next closest healthcare companies are UnitedHealth Group (UNH) and Johnson & Johnson (JNJ), with market caps of $448 billion and $406 billion, respectively. \n For the latest news, Facebook, Twitter and Instagram.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}